| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | 3.8% | $51,436,214 | 2,047,620 | Venrock Healthcare Capital Partners III, L.P. | 30 Jun 2025 | |||
| Bain Capital Life Sciences Fund, L.P. | 3% | $46,597,344 | 1,867,629 | Bain Capital Life Sciences Fund, L.P. | 30 Sep 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 57,844,608 | $1,443,142,875 | +$236,461,386 | $24.95 | 83 |
| 2025 Q2 | 45,040,180 | $792,712,813 | +$1,806,103 | $17.6 | 60 |
| 2025 Q1 | 44,939,067 | $705,543,867 | +$4,132,739 | $15.7 | 52 |
| 2024 Q4 | 44,644,168 | $855,824,077 | -$7,190,155 | $19.17 | 54 |
| 2024 Q3 | 45,045,428 | $834,243,398 | +$34,119,580 | $18.52 | 51 |
| 2024 Q2 | 43,008,763 | $808,565,649 | +$10,680,383 | $18.8 | 36 |
| 2024 Q1 | 42,425,740 | $980,459,437 | +$36,728,417 | $23.11 | 35 |
| 2023 Q4 | 40,745,703 | $1,142,917,292 | +$327,949,428 | $28.05 | 36 |
| 2023 Q3 | 29,067,102 | $606,630,419 | +$4,468,799 | $20.87 | 21 |
| 2023 Q2 | 28,913,752 | $441,577,880 | +$109,619,000 | $15.14 | 21 |
| 2023 Q1 | 21,781,494 | $173,888,454 | +$3,756,313 | $8.06 | 21 |
| 2022 Q4 | 21,301,855 | $239,644,411 | -$1,830,525 | $11.25 | 25 |
| 2022 Q3 | 22,314,954 | $173,600,000 | -$317,120 | $7.67 | 21 |
| 2022 Q2 | 22,353,338 | $494,009,000 | +$14,911,660 | $22.1 | 20 |
| 2022 Q1 | 21,685,388 | $397,090,000 | +$838,867 | $18.14 | 22 |
| 2021 Q4 | 21,647,018 | $321,068,000 | -$1,695,268 | $14.39 | 22 |
| 2021 Q3 | 21,631,638 | $380,302,000 | -$6,827,497 | $17.73 | 25 |
| 2021 Q2 | 21,995,815 | $406,288,000 | -$1,442,853 | $18.62 | 28 |
| 2021 Q1 | 22,025,122 | $616,507,000 | +$616,507,000 | $27.99 | 33 |